FY2024 EPS Estimates for Moderna Cut by Leerink Partnrs

Moderna, Inc. (NASDAQ:MRNA) – Analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of Moderna in a note issued to investors on Monday, January 13th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($9.61) per share for the year, down from their prior estimate of ($9.50). The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. Leerink Partnrs also issued estimates for Moderna’s Q4 2024 earnings at ($3.28) EPS, Q1 2025 earnings at ($2.58) EPS, Q2 2025 earnings at ($2.56) EPS, Q3 2025 earnings at ($2.55) EPS, FY2025 earnings at ($10.28) EPS, FY2026 earnings at ($7.73) EPS and FY2027 earnings at ($4.13) EPS.

MRNA has been the subject of several other research reports. JPMorgan Chase & Co. cut their price objective on Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday, November 26th. Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler reissued an “overweight” rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Berenberg Bank upped their target price on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday. Finally, HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Monday, November 18th. Four research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $75.58.

Moderna Trading Down 2.9 %

NASDAQ:MRNA opened at $33.76 on Thursday. The company has a 50 day simple moving average of $41.11 and a two-hundred day simple moving average of $67.32. The company has a market cap of $12.99 billion, a PE ratio of -5.80 and a beta of 1.60. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna has a 12 month low of $31.94 and a 12 month high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.39) earnings per share.

Hedge Funds Weigh In On Moderna

Hedge funds have recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna during the second quarter valued at approximately $26,000. Envestnet Asset Management Inc. grew its position in Moderna by 78.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 109,733 shares of the company’s stock valued at $13,031,000 after acquiring an additional 48,316 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in Moderna in the second quarter worth $426,000. Dimensional Fund Advisors LP lifted its position in shares of Moderna by 2.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock worth $169,542,000 after purchasing an additional 29,566 shares during the last quarter. Finally, Edgestream Partners L.P. purchased a new stake in shares of Moderna during the second quarter valued at $1,672,000. 75.33% of the stock is currently owned by institutional investors.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 2,664 shares of company stock valued at $115,210 in the last ninety days. Insiders own 15.20% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.